CD274 and neoplasm: Additionally, this article provides an in-depth analysis of mechanisms contributing to immune resistance-such as loss of tumor neoantigens and dysregulation of key signaling pathways-and critically appraises the limitations of established biomarkers, including PD-L1 expression and tumor mutational burden (TMB), alongside emerging developments in biomarker discovery.